Retinal pigment epithelium tears after intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration

Retina

Volumn 27, Issue 5, 2007, Pages 535-540

  Ronan, Shawn M ^a   Yoganathan, Pradeepa ^b   Chien, Fred Y ^c   Corcóstegui, Iñigo A ^d   Blumenkranz, Mark S ^c   Deramo, Vincent A ^b   Elner, Susan G ^a   Fastenberg, David A ^b   Johnson, Mark W ^a   López, Mauricio ^d   Mateo, Carlos ^d   Moshfeghi, Darius M ^c   Navarro, Rafael ^d   Rosenblatt, Brett J ^b   Sanislo, Steven R ^c   Saxe, Stephen J ^a   Zacks, David N ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^c STANFORD UNIVERSITY   (United States)

^d Ocular Microsurgery Institute   (Spain)

Author keywords

Age related macular degeneration; Bevacizumab (Avastin); Intravitreal injection; Ranibizumab; Retinal pigment epithelium detachment; Retinal pigment epithelium tear

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; TRIAMCINOLONE;

AGED; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; FEMALE; HUMAN; INCIDENCE; LASER COAGULATION; MALE; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA PIGMENT EPITHELIOPATHY; RETINA TEAR; RETROSPECTIVE STUDY; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INJECTIONS; MACULAR DEGENERATION; MALE; PIGMENT EPITHELIUM OF EYE; RETINAL DETACHMENT; RETINAL PERFORATIONS; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 34250176573     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3180cc2645     Document Type: Article

References (22)

1. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36:331-335.
2. Avery RL. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 2006;26:252-254.
3. Mason JO, Albert MA, Vail R. Intravitreal bevacizumab (Avastin) for refractory pseudophakic cystoid macular edema. Retina 2006;26:356-357.
4. Iturralde D, Spaide RF, Meyerle CB, et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion. Retina 2006;26:279-284.
5. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of diabetic retinopathy complicated by vitreous hemorrhage. Retina 2006;26:275-278.
6. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the Internet to assess drug safety worldwide. Br J Ophthalmol 2006;90:1344-1349.
7. Manzona RPA, Gholam PA, Khan P, Kivilcim M. Testing intravitreal toxicity of bevacizumab (Avastin). Retina 2006;26:257-261.
8. Maturi RK, Bleau LA, Wilson DL. Electrophysiologic findings after intravitreal bevacizumab (Avastin) injection. Retina 2006;26:270-274.
9. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113:363-372.
10. Yoganathan P, Deramo VA, Lai JC, et al. Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration. Retina 2006;26:994-998.
11. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 2006;26:279-284.
12. Bashshur ZF, Bazarbachi A, Schakal A, et al. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006;142:1-9.
13. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006;26:495-511.
14. Yoe JH, Marcus S, Murrphy RP. Retinal pigment epithelial tears: patterns and prognosis. Ophthalmology 1988;95:8-13.
15. Pece A, Introini U, Bottoni F, Brancato R. Acute retinal pigment epithelial tear after photodynamic therapy. Retina 2001;21:661-665.
16. Michels S, Aue A, Simader C, et al. Retinal pigment epithelium tears Following verteporfin therapy combined with intravitreal triamcinolone. Am J Ophthalmol 2006;141:396-398.
17. Dhalla MS, Blinder KJ, Tewari A, et al. Retinal pigment epithelial tear following intravitreal pegaptanib sodium. Am J Ophthalmol 2006;141:752-754.
18. Singh RP, Sears JE. Retinal pigment epithelial tear after pegaptanib injection for exudative age-related macular degeneration. Am J Ophthalmol 2006;142:160-162.
19. Rosenfeld PJ, Heier JS, Hantsbarger G, Shams N. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology 2006;113:632.
20. Meyer CH, Mennel S, Schmidt JC, Kroll P. Acute retinal pigment epithelial tear following intravitreal bevacizumab (Avastin) injection for occult choroidal neovascularisation secondary to age related macular degeneration. Br J Ophthalmol 2006;90:1207-1208.
21. Hoskin A, Bird AC, Sehmi K. Tears of detached retinal pigment epithelium. Br J Ophthalmol 1981;65:417-422.
22. Gass JD. Pathogenesis of tears of the retinal pigment epithelium. Br J Ophthalmol 1984;68:513-519.